As previously discussed, in December 2016, the U.S. Judicial Panel on Multidistrict Litigation ordered Invokana cases consolidated into a Multi-District Litigation (MDL) in the United States District Court, District of New Jersey (MDL 2750).
Since the inception of the litigation, more than one thousand cases have been filed in the District of New Jersey. Cases filed in the MDL allege that individuals taking Invokana are at an increased risk of an amputation of a lower extremity (leg or toe), as well as an increased risk of suffering from ketoacidosis, which is a condition the causes the body to produce high levels of blood acids called ketones. Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, fatigue, and difficulty breathing.